WO2023110824 - NOVEL INTEGRIN ASSOCIATED PROTEIN (IAP)
National phase entry is expected:
Publication Number
WO/2023/110824
Publication Date
22.06.2023
International Application No.
PCT/EP2022/085538
International Filing Date
13.12.2022
Title **
[English]
NOVEL INTEGRIN ASSOCIATED PROTEIN (IAP)
[French]
NOUVELLE PROTÉINE ASSOCIÉE À L'INTÉGRINE (IAP)
Applicants **
NOVO NORDISK A/S
Novo Allé
2880 Bagsværd, DK
Inventors
YANG, Che
Novo Alle 1
2880 Bagsværd, DK
SCHLUCKEBIER, Gerd
Novo Alle 1
2880 Bagsværd, DK
RASMUSSEN, Salka Elbøl
Novo Alle 1
2880 Bagsværd, DK
CHRISTOPHERSEN, Nicolaj Strøyer
Novo Alle 1
2880 Bagsværd, DK
Priority Data
21214877.9
15.12.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1191 | |
| EPO | Filing, Examination | 4808 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3310 |
Total: 10475 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to novel Integrin associated proteins, cells, compositions, and pharmaceutical products which improve cellular therapy.[French]
La présente invention concerne de nouvelles protéines associées à l'intégrine, des cellules, des compositions et des produits pharmaceutiques qui améliorent la thérapie cellulaire.